Xiao-Xiao Lai

Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database

Abstract Background Bexagliflozin and velagliflozin are currently the only sodium-glucose cotransporter 2 inhibitors approved by the United States Food and Drug Administration (FDA) for treating diabetes in cats. There are limited real-world safety reports on their associated adverse events (AEs). Hypothesis/Objectives...